ACC 2019 Roundup – ReCor touts six-month Paradise renal denervation study results
This study effectively shows that by giving health consumers the tools they need to better manage their health, we can empower them to live healthier lives,” senior study author and chief medical officer Dr. Bimal Shah said in a prepared statement.
Read more
Neovasc presents Reducer data
Neovasc (NSDQ:NVCN) said today that it released data on its Neovasc Reducer device during the American College of Cardiology’s 68th Annual Scientific Sessions in New Orleans.
During the session, researchers explored the treatment of refractory angina in patients with no options, Vancouver-based Neovasc said, touting its Red...
Source: Mass Device - March 19, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Featured Patient Monitoring ReCor Medical Source Type: news
Electronic Order Set May Reduce Inappropriate ECG Monitoring
WEDNESDAY, March 6, 2019 -- Use of electronic order sets is a safe and effective way to enhance appropriate electrocardiographic (ECG) monitoring of hospitalized patients, according to a study published in the March issue of the American Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 6, 2019 Category: Pharmaceuticals Source Type: news
Is AI a Fad or a Sure-Fire Thing in Medtech?
The growing popularity of artificial intelligence in medtech was pretty obvious in 2018. The use of AI in creating new applications or enhancing existing ones was perhaps the hottest trend in the medical device industry last year. But that was 2018. What about this year and just what does the future hold for AI.
One medtech executive/entrepreneur thinks that 2019 will be the year of validation for AI. Yann Fleureau, the co-founder and CEO of Cardiologs, a Paris-based company building deep learning algorithms for ECG analysis, spoke with MD+DI about one of the AI and its expected impact.
“I think we will s...
Source: MDDI - March 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news
HEART Care Pathway Reduces Admission, Stress Testing in ACS
THURSDAY, Feb. 28, 2019 -- Implementing a history, electrocardiogram, age, risk factors, and troponin (HEART) care pathway can reduce use of hospital care and noninvasive stress testing among patients with suspected acute coronary syndrome (ACS),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2019 Category: Pharmaceuticals Source Type: news
AliveCor Appoints Dr. Jacqueline Shreibati, Chief Medical Officer
MOUNTAIN VIEW, Calif., Feb. 26, 2019 -- (Healthcare Sales & Marketing Network) -- AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced Jacqueline Shreibati, MD, MS, FACC, as Chief Medical Officer of the company.... Devices, Cardiology, Personnel AliveCor, KardiaMobile, ECG (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 26, 2019 Category: Pharmaceuticals Source Type: news
Biotronik Has a New DES Added to its Repertoire
FDA has just signed off on Biotronik’s Orsiro drug-eluting stent (System). The Lake Oswego, OR-based company claims the stent is the first and ultrathin DES to outperform Abbott Laboratories’, Xience stent, which is known as the clinical standard.
Biotronik said its first implants will occur this week and that it will be available in health systems in the early part of this year. The company has had CE mark for Orsiro since 2011.
Perhaps the biggest selling point of the technology is the ultrathin strut design.
“Thinner struts are different in that they potentially crea...
Source: MDDI - February 25, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news
What Is the Most Common Type of Cardiomyopathy?
Discussion
Barth syndrome is characterized by a dilated cardiomyopathy, proximal skeletal muscle weakness, neutropenia and short stature that usually presents at birth or soon after. It is a rare X-linked recessive disease process caused by mutations in the TAZ gene. The TAZ gene codes for tafazzin which alters cardiolipin in mitochondria. Characteristic facies can be seen especially in infancy including a tall and broad forehead, prominent chin and full cheeks, larger ears, and deep-set eyes. Most patients present at birth or soon afterwards but some may not until later in life. Life expectancy is reduced with many childr...
Source: PediatricEducation.org - February 25, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Syncope Monitoring in ED: 2 Hours Okay for Low-Risk Patients Syncope Monitoring in ED: 2 Hours Okay for Low-Risk Patients
Patients with syncope who present to the emergency department and who are at low risk for serious arrhythmia can be discharged home after 2 hours of electrocardiogram monitoring, new data show.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 13, 2019 Category: Cardiology Tags: Emergency Medicine News Source Type: news
Underfunding drives practices to stop providing non-core services
Eight GP practices in Buckinghamshire have decided to discontinue the provision of underfunded non-core services.
Writing to Berkshire, Buckinghamshire& Oxfordshire (Bucks, Berks& Oxon) LMCs last December, the practices announced their decision to cease the provision of seven different services by August this year at the latest.
These include ear syringing, 24-hour blood pressure monitoring, spirometry for diagnosis, ECGs, ring pessary, PSA monitoring and MGUS monitoring. Hide related content:
Show related contentread more (Source: Management in Practice)
Source: Management in Practice - February 11, 2019 Category: Practice Management Authors: Angela Sharda Tags: *** Editor ' s Pick Latest News Source Type: news
FDA OKs ECG Feature on Verily Study Watch for Research FDA OKs ECG Feature on Verily Study Watch for Research
The Verily Study Watch records, stores, transfers, and displays single-channel electrocardiogram data as part of clinical research studies.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 21, 2019 Category: Neurology Tags: Cardiology News Alert Source Type: news
FDA clears Verily ’ s Study Watch for on-demand ECG
Alphabet‘s (NSDQ:GOOGL) life sciences group, Verily, said today that it won 510(k) clearance from the FDA for its Study Watch for its on-demand electrocardiogram feature.
In a blog post published today, the head of Verily’s cardiovascular health innovations unit, Dr. Michael McConnell, wrote that the Study Watch indication covers the recording, storage, transfer and display of single-channel ECG rhythms.
“The ability to take an on-demand, single-lead ECG, can support both population-based research and an individual’s clinical care,” McConnell wrote. “Receiving this clearance showcases our c...
Source: Mass Device - January 18, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Verily Source Type: news
Not Just Acid Reflux: The Need to Think Worst First
Discussion
Heart disease is the leading cause of death in the United States.1 This year, 720,000 Americans will have a new coronary event—defined as first hospitalized myocardial infarction (MI) or coronary heart disease death—and around 335,000 will have a recurrent event. Approximately 35% of people who experience a coronary event in a given year and around 14% of patients who have an acute coronary syndrome will die from it.1 Roughly 60% of patients with an acute coronary syndrome are transported to the emergency department via ambulance.2–4.
Up to one-third of patients experiencing an MI may not complain of chest...
Source: JEMS Special Topics - January 13, 2019 Category: Emergency Medicine Authors: Stephen Sanko, MD, FACEP Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news
Artificial Intelligence Can Use Routine ECGs to ID Heart Disease
FRIDAY, Jan. 11, 2019 -- Artificial intelligence (AI) can identify asymptomatic left ventricular dysfunction (ALVD) using results from a routine electrocardiogram (ECG), according to a research letter published online Jan. 7 in Nature... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2019 Category: Pharmaceuticals Source Type: news
iRhythm Finds Its Groove at the Intersection of Cardiology and AI
iRhythm Technologies has the distinct feature of being at the intersection of some of the hottest markets in medtech – cardiology, wearables, and artificial intelligence. The San Francisco-based company has developed, the Zio Patch XT, a wearable technology to monitor heart rate activity for up to 14 days and is set to present at the 37th Annual J.P. Morgan Healthcare Conference this week.
Tim King, iRhythm’s president and CEO spoke to MD+DI ahead of the company’s presentation about the company's success and its goals going forward.
“The tool of choice...
Source: MDDI - January 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Digital Health Source Type: news
Mayo Clinic research uses artificial intelligence to develop inexpensive, widely available early detector of silent heart disease
ROCHESTER, Minn. -- A Mayo Clinic study finds that applying artificial intelligence (AI) to a widely available, inexpensive test - the electrocardiogram (EKG) - results in a simple, affordable early indicator of asymptomatic left ventricular dysfunction, which is a precursor to heart failure. The research team found that the AI/EKG test accuracy compares favorably with [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 7, 2019 Category: Databases & Libraries Source Type: news
